

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **June 30, 2017**

**TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: **000-54208**

**BioCorRx, Inc**

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

90-0967447

(I.R.S. Employer Identification No.)

**2390 East Orangewood Avenue, Suite 575**

**Anaheim, California 92806**

(Address of principal executive offices) (zip code)

**(714) 462-4880**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 11, 2017, there were 242,136,285 shares of registrant's common stock outstanding.

---

## TABLE OF CONTENTS

### PART FINANCIAL INFORMATION

#### I.

ITEM 1. Financial Statements	
<u>Condensed consolidated balance sheets as of June 30, 2017 (unaudited) and December 31, 2016</u>	3
<u>Condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016 (unaudited)</u>	4
<u>Condensed consolidated statement of stockholders' deficit for the six months ended June 30, 2017 (unaudited)</u>	5
<u>Condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 (unaudited)</u>	6
<u>Notes to condensed consolidated financial statements (unaudited)</u>	7-21
ITEM 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	22
ITEM 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	29
ITEM 4. <u>Controls and Procedures</u>	29

### PART OTHER INFORMATION

#### II.

ITEM 1. <u>Legal Proceedings</u>	30
ITEM <u>Risk Factors</u>	
<u>1A.</u>	30
ITEM 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
ITEM 3. <u>Defaults Upon Senior Securities</u>	30
ITEM 4. <u>Mine Safety Disclosures</u>	30
ITEM 5. <u>Other Information</u>	30
ITEM 6. <u>Exhibits</u>	31
SIGNATURES	32

**BIOCORRX INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

	<b>June 30, 2017</b>	<b>December 31, 2016</b>
	<u>(unaudited)</u>	<u></u>
<b>ASSETS</b>		
Current assets:		
Cash	\$ 845,067	\$ 92,455
Accounts receivable, net	51,750	-
Prepaid expenses	6,934	8,400
Total current assets	<u>903,751</u>	<u>100,855</u>
Property and equipment, net	19,107	22,164
Other assets:		
Restricted cash	50,000	50,000
Intellectual property, net	265,932	279,729
Deposits, long term	17,634	17,634
Total other assets	<u>333,566</u>	<u>347,363</u>
Total assets	<u>\$ 1,256,424</u>	<u>\$ 470,382</u>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
Current liabilities:		
Accounts payable and accrued expenses, including related party payables of \$84,063 and \$195,584, respectively	\$ 572,976	\$ 937,938
Deferred revenue, short term	301,789	432,836
Settlement payable	45,000	315,000
Convertible notes payable, short term, net of debt discount	-	87,033
Notes payable, net of debt discount, short term portion	-	172,748
Notes payable, net of debt discount, related party	186,172	210,761
Derivative liability	-	294,807
Total current liabilities	<u>1,105,937</u>	<u>2,451,123</u>
Long term debt:		
Deferred revenue, long term	466,954	613,428
Convertible notes payable, long term, net of debt discount	1,266,062	688,783
Warrant liability	111,146	26,903
Derivative liability	-	4,820,473
Total long term debt	<u>1,844,162</u>	<u>6,149,587</u>
Total liabilities	<u>2,950,099</u>	<u>8,600,710</u>
Stockholders' deficit:		
Preferred stock, no par value and \$0.001 par value; 600,000 authorized as of June 30, 2017 and December 31, 2016		
Preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of June 30, 2017 and December 31, 2016	16,000	16,000
Series B Preferred stock, no par value; 160,000 designated; 160,000 shares issued and outstanding as of June 30, 2017 and December 31, 2016	5,616	5,616
Common stock, \$0.001 par value; 525,000,000 shares authorized, 242,136,285 and 181,804,501 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	242,136	181,805
Common stock subscribed	100,000	100,000
Additional paid in capital	44,109,037	10,701,116
Accumulated deficit	(46,166,464)	(19,134,865)
Total stockholders' deficit	<u>(1,693,675)</u>	<u>(8,130,328)</u>
Total liabilities and stockholders' deficit	<u>\$ 1,256,424</u>	<u>\$ 470,382</u>

See the accompanying notes to the unaudited condensed consolidated financial statements

**BIOCORRX INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
*(unaudited)*

	<b>Three months ended June</b>		<b>Six months ended June 30,</b>	
	<b>30,</b>			
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
Revenues, net	\$ 210,544	\$ 187,912	\$ 344,771	\$ 418,325
Operating expenses:				
Cost of implants and other costs	166,665	46,185	190,015	86,638
Research and development	43,339	-	51,570	-
Selling, general and administrative	778,693	553,224	1,285,293	944,463
Termination of licensing agreement	-	-	-	132,804
Depreciation and amortization	8,465	795	16,854	1,368
Total operating expenses	997,162	600,204	1,543,732	1,165,273
Loss from operations	(786,618)	(412,292)	(1,198,961)	(746,948)
Other income (expenses):				
Gain on settlement of debt	285,924	-	285,924	-
Interest expense, net	(459,064)	(223,127)	(10,220,569)	(388,359)
Gain (loss) on change in fair value of derivative liability	12,263,680	(438,344)	(15,897,993)	(467,041)
Total other income (expenses)	12,090,540	(661,471)	(25,832,638)	(855,400)
Income (loss) before income taxes	11,303,922	(1,073,763)	(27,031,599)	(1,602,348)
Income taxes	-	-	-	-
Net Income (loss)	\$ 11,303,922	\$ (1,073,763)	\$ (27,031,599)	\$ (1,602,348)
Net income (loss) per common share, basic	\$ 0.05	\$ (0.01)	\$ (0.12)	\$ (0.01)
Net income (loss) per common share, diluted	\$ 0.02	\$ (0.01)	\$ (0.12)	\$ (0.01)
Weighted average number of common shares outstanding, basic	241,730,516	165,394,501	222,279,257	165,166,479
Weighted average number of common shares outstanding, diluted	579,668,702	165,394,501	222,279,257	165,166,479

See the accompanying notes to the unaudited condensed consolidated financial statements

**BIOCORRX INC.**  
**CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT**  
**SIX MONTHS ENDED JUNE 30, 2017**

	<u>Preferred stock</u>		<u>Series B Preferred stock</u>		<u>Common stock</u>		<u>Common stock Subscribed</u>	<u>Additional Paid in Capital</u>	<u>Accumulated Deficit</u>	<u>Total</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>				
Balance, December 31, 2016	80,000	\$ 16,000	160,000	\$ 5,616	181,804,501	\$181,805	\$ 100,000	\$10,701,116	\$ (19,134,865)	\$ (8,130,328)
Common stock issued for services rendered	-	-	-	-	3,003,118	3,003	-	195,905	-	198,908
Common stock issued in settlement of convertible debt	-	-	-	-	13,662,000	13,662	-	1,352,538	-	1,366,200
Sale of common stock	-	-	-	-	43,666,666	43,666	-	896,334	-	940,000
Reclassify fair value of debt derivative at modification of note payable	-	-	-	-	-	-	-	30,806,073	-	30,806,073
Fair value of vested options	-	-	-	-	-	-	-	157,071	-	157,071
Net loss	-	-	-	-	-	-	-	-	(27,031,599)	(27,031,599)
Balance, June 30, 2017 <i>(unaudited)</i>	<u>80,000</u>	<u>\$ 16,000</u>	<u>160,000</u>	<u>\$ 5,616</u>	<u>242,136,285</u>	<u>\$242,136</u>	<u>\$ 100,000</u>	<u>\$44,109,037</u>	<u>\$ (46,166,464)</u>	<u>\$ (1,693,675)</u>

See the accompanying notes to the unaudited condensed consolidated financial statements

**BIOCORRX INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
*(unaudited)*

	<b>Six months ended June</b>	
	<b>30,</b>	
	<b>2017</b>	<b>2016</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$(27,031,599)	\$(1,602,348)
Adjustments to reconcile net loss to cash flows used in operating activities:		
Depreciation and amortization	16,854	1,368
Bad debt expense	-	8,750
Termination of licensing agreement	-	132,804
Non cash interest	9,363,244	21,722
Amortization of debt discount	710,658	286,627
Stock based compensation	355,979	101,217
Gain on settlement of debt	(285,924)	-
Change in fair value of option modifications	-	53,858
Change in fair value of derivative liabilities	15,897,993	467,041
Changes in operating assets and liabilities:		
Accounts receivable	(51,750)	(15,500)
Prepaid expenses and other current assets	1,466	(5,233)
Accounts payable and accrued expenses	(89,040)	(245,265)
Settlement payable	(270,000)	-
Deferred revenue	(277,521)	(215,826)
Net cash used in operating activities	(1,659,640)	(1,010,785)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of equipment	-	(14,124)
Payment of long term deposit	-	(17,634)
Payment for intellectual property	-	(55,648)
Net cash used in investing activities	-	(87,406)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from sale of common stock	940,000	-
Proceeds from convertible notes payable	1,660,000	2,264,448
Repayments of notes payable	(187,748)	(211,500)
Net cash provided by financing activities	2,412,252	2,052,948
Net increase in cash	752,612	954,757
Cash, beginning of the period	92,455	220,060
Cash, end of period	<u>\$ 845,067</u>	<u>\$ 1,174,817</u>
<b>Supplemental disclosures of cash flow information:</b>		
Interest paid	\$ 10,507	\$ 2,418
Taxes paid	\$ -	\$ -
<b>Non cash financing activities:</b>		
Reclassify fair value of debt derivative at payoff of note payable	\$ -	\$ 262,271
Reclassify fair value of debt derivative at note modification	\$ 30,806,073	\$ -
Common stock issued in settlement of convertible notes payable	\$ 220,000	\$ -

See the accompanying notes to the unaudited condensed consolidated financial statements

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

**NOTE 1 – BUSINESS AND RECAPITALIZATION**

BioCorRx Inc., through its subsidiaries, provides an innovative alcoholism and opioid addiction treatment program called the BioCorRx® Recovery Program, as well as research and development of related products that can empower patients to succeed in their overall recovery. We offer a unique treatment philosophy that combines medical intervention and a proprietary counseling program (plus peer support program) specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. We are also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Specifically, the company is developing an injectable and implantable naltrexone with the goal of future regulatory approval with the Food and Drug Administration.

On January 7, 2014, the Company changed its name from Fresh Start Private Management, Inc. to BioCorRx Inc. In addition, effective February 20, 2014, the Company's quotation symbol on the Over-the-Counter Bulletin Board was changed from CEYY to BICX.

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the newly formed sub issued 21.9% ownership to officers of the Company with the Company retaining 78.1%. As of June 30, 2017, there were no significant assets or liabilities in BioCorRx Pharmaceuticals, Inc., or operations since its formation.

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES**

Interim Financial Statements

The following (a) condensed consolidated balance sheet as of December 31, 2016, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of results that may be expected for the year ending December 31, 2017. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission ("SEC") on April 13, 2017.

Basis of presentation

The consolidated condensed financial statements include the accounts of BioCorRx Inc., its wholly owned subsidiary, Fresh Start Private, Inc. and its majority owned subsidiary, BioCorRx Pharmaceuticals, Inc. (hereafter referred to as the "Company" or "BioCorRx"). All significant intercompany balances and transactions have been eliminated in consolidation.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

Revenue Recognition

The Company generates revenue from services and product sales. Revenue is recognized in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition ("ASC 605-10") which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the services delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related revenue is recorded. The Company defers any revenue for which the services has not been performed or is subject to refund until such time that the Company and the customer jointly determine that the services has been performed or no refund will be required.

We license proprietary products and protocols to customers under licensing agreements that allow those customers to utilize the products and protocols in services they provide to their customers. The timing and amount of revenue recognized from license agreements depends upon a variety of factors, including the specific terms of each agreement. Such agreements are reviewed for multiple elements. Multiple elements can include amounts related to initial non-refundable license fees for the use of our products and protocols and additional royalties on covered services.

Revenue is only recognized after all of the following criteria are met: (1) written agreements have been executed; (2) delivery of technology or intellectual property rights has occurred; (3) fees are fixed or determinable; and (4) collectability of fees is reasonably assured.

Under these license agreements, the Company receives an initial non-refundable license fee and in some cases, additional running royalties. Generally, the Company defers recognition of non-refundable upfront fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of its performance under the other elements of the arrangement. License fees collected from Licensees but not yet recognized as income are recorded as deferred revenue and amortized as income earned over the expected economic life of the related contract.

Use of Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of stock-based compensation, derivative and warrant liabilities, the fair value of other equity and debt instruments and allowance for doubtful accounts.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At June 30, 2017 and December 31, 2016, deposits in excess of FDIC limits were \$645,067 and \$-0-, respectively.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

Accounts Receivable

Accounts receivable are recorded at original invoice amount less an allowance for uncollectible accounts that management believes will be adequate to absorb estimated losses on existing balances. Management estimates the allowance based on collectability of accounts receivable and prior bad debt experience. Accounts receivable balances are written off upon management's determination that such accounts are uncollectible. Recoveries of accounts receivable previously written off are recorded when received. Management believes that credit risks on accounts receivable will not be material to the financial position of the Company or results of operations. The allowance for doubtful accounts was \$79,250 as of June 30, 2017 and December 31, 2016.

Fair Value of Financial Instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2017 and December 31, 2016. The respective carrying value of certain financial instruments approximated their fair values. These financial instruments include cash, stock based compensation and notes payable. The fair value of the Company's convertible securities is based on management estimates and reasonably approximates their book value.

See Footnote 9 and 11 for derivative liabilities and Footnote 10 and 12 for stock based compensation and other equity instruments.

Restricted Cash

The Company is required to maintain in its bank accounts at all times no less than 10% of the outstanding principle of its convertible debt issued June 10, 2016. The amount held may be reduced upon noteholder approval. The Cash held must be unrestricted and not subject to any liens. As of June 30, 2017 and December 31, 2016, the Company's restricted cash balance of \$50,000 was classified as other assets in the accompanying balance sheet.

Segment Information

Accounting Standards Codification subtopic Segment Reporting 280-10 ("ASC 280-10") establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein materially represents all of the financial information related to the Company's principal operating segment.

Long-Lived Assets

The Company follows FASB ASC 360-10-15-3, "Impairment or Disposal of Long-lived Assets," which established a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset's estimated useful life, which is five years for furniture and all other equipment. Expenditures for maintenance and repairs are expensed as incurred.

Net Income (loss) Per Share

The Company accounts for net income (loss) per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"), which requires presentation of basic and diluted earnings per share ("EPS") on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS.

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of any potentially issuable common shares.

Diluted net loss share is calculated by including any potentially dilutive share issuances in the denominator. As of June 30, 2017 and 2016, potentially dilutive shares issuances were comprised of convertible notes, warrants and stock options.

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding for the six months ended June 30, 2017 and for the three and six months ended June 30, 2016, as they would be anti-dilutive:

	<b>June 30, 2017</b>	<b>June 30, 2016</b>
Shares underlying options outstanding	47,850,000	47,850,000
Shares underlying warrants outstanding	2,430,000	2,630,000
Shares underlying convertible notes outstanding	305,433,186	1,833,333
	<u>355,713,186</u>	<u>52,313,333</u>

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred. The Company charged to operations \$44,132 and \$63,771 as advertising costs for the three and six months ended June 30, 2017 and \$70,222 and \$138,744 for the three and six months ended June 30, 2016, respectively.

Research and development costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of \$43,339 and \$51,570 for the three and six months ended June 30, 2017, respectively, and \$-0- for the three and six months ended June 30, 2016.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At June 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges.

At June 30, 2017 and December 31, 2016, the Company had outstanding convertible notes and/or warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 10 and Note 12).

Stock Based Compensation

Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete.

As of June 30, 2017, there were 47,850,000 stock options outstanding, of which 31,350,000 were vested and exercisable. As of June 30, 2016, there were 47,850,000 stock options outstanding, of which 14,850,000 were vested and exercisable.

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is more likely than not that these deferred income tax assets will not be realized.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of June 30, 2017 and 2016, the Company has not recorded any unrecognized tax benefits.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

**NOTE 3 – GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS**

As of June 30, 2017, the Company had cash of \$845,067 and working capital deficit of \$202,186. During the six months ended June 30, 2017, the Company used net cash in operating activities of \$1,659,640. The Company has not yet generated any significant revenues, and has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

During the six months ended June 30, 2017, the Company raised \$1,660,000 in cash proceeds from the issuance of convertible notes payable and \$940,000 proceeds from the sale of common stock. The Company believes that its current cash on hand will be sufficient to fund its projected operating requirements through December 2017.

The Company's primary source of operating funds since inception has been from proceeds from private placements of convertible and other debt and the sale of common stock. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

**NOTE 4 – PROPERTY AND EQUIPMENT**

The Company's property and equipment at June 30, 2017 and December 31, 2016:

	<b>June 30, 2017</b>	<b>December 31, 2016</b>
Office equipment	\$ 34,234	\$ 34,234
Computer equipment	2,574	2,574
	36,808	36,808
Less accumulated depreciation	(17,701)	(14,644)
	<u>\$ 19,107</u>	<u>\$ 22,164</u>

Depreciation expense charged to operations amounted to \$1,529 and \$3,057, respectively, for the three and six months ended June 30, 2017; and \$795 and \$1,368, respectively, for the three and six months ended June 30, 2016.

**NOTE 5 – INTELLECTUAL PROPERTY/ LICENSING RIGHTS**

On June 30, 2015, the Company acquired the complete rights, title and interest in the Naltrexone Implant Formulation used specifically in the BioCorRx Recovery Program for an aggregate purchase price of \$1,132,000 comprised of an obligation to pay \$1,000,000 over 14 months starting October 1, 2015 and 3,000,000 of the Company's common stock at the market value of \$0.044 per share as of the date of the agreement. The Company estimated a useful life of 10 years.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

On March 31, 2016, the parties agreed to terminate the above described acquisition and to cancel any and all obligations assumed under the agreement. In connection with the cancellation, the Company recorded a loss on termination of licensing agreement of \$132,804.

On January 26, 2016, the Company entered into an asset purchase agreement to acquire intellectual and contractual rights for all of North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of \$55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life. Amortization charged to operations amounted to \$6,937 and \$13,797, respectively, for the three and six months ended June 30, 2017.

On July 28, 2016, the Company and Therakine, Ltd., an Irish private company limited by shares ("Therakine"), entered into a Development, Commercialization and License Agreement (the "Agreement"). Therakine has know-how and patents related to sustained release drug delivery technology (the "Technology"). Pursuant to the Agreement, Therakine granted the Company an exclusive license to utilize the Technology in developing injectable naltrexone products to treat patients suffering addiction to opioids, methamphetamines, cocaine, or alcohol. The Company is permitted to sell on a worldwide basis the products that utilize the Technology. The Agreement expires when the Company's last valid claim to Therakine's patents expires. Upon expiration of the Agreement, the licenses granted will become irrevocable and fully paid up.

The Company agreed to pay, in return for the license to the Technology, up to \$2,750,000 in milestone payments and royalties ranging from 5% to 12% of net sales of products that use the Technology with aggregate payments per year of not less than \$250,000. The Company is also required to pay a percentage of any sublicense income it receives related to products that use the Technology. In the event Therakine enters into a license agreement with a third party for products unrelated to injectable naltrexone that use the Technology, Therakine will pay the Company a percentage of its income from these products. As of June 30, 2017 and December 31, 2016, the Company has paid an aggregate of \$250,000 of which \$75,000 was held in escrow until certain drug levels are met at December 31, 2016.

In 2016, the Company assigned and Therakine agreed to assign the rights under the Therakine Agreement, to BioCorRx Pharmaceuticals, Inc., the Company majority owned subsidiary.

The Company amortizes license fees over the shorter of the economic life of the related contract life or contract terms for each licensee. The remaining unamortized aggregate balance of deferred revenue as of June 30, 2017 and December 31, 2016 was \$768,743 and \$1,046,264, respectively.

**NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consisted of the following as of June 30, 2017 and December 31, 2016:

	<b>June 30, 2017</b>	<b>December 31, 2016</b>
Amounts payable	\$ 266,026	\$ 768,345
Interest payable on notes payable	305,334	168,785
Deferred rent	1,616	808
	<u>\$ 572,976</u>	<u>\$ 937,938</u>

During the six months ended June 30, 2017, the Company settled old outstanding debt with vendors recognizing a \$275,924 gain on settlement of debt.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

**NOTE 7 – SETTLEMENT PAYABLE**

On March 9, 2016, Jorge Andrade (former Company's Chief Executive Officer) and Terranautical Global Investments, Inc. filed with the Eighth Judicial District Court in Clark County, Nevada a lawsuit claiming unpaid compensation, bonuses and previous loans in aggregate of \$316,000 plus accrued interest and damages.

On March 21, 2016, the Plaintiff and the Company entered into a settlement agreement whereby the Company agreed to settle for a cash payment of \$250,000 due December 16, 2016. On March 8, 2017, the settlement agreement was amended with an initial payment of \$190,000 to be delivered by March 15, 2017 and the remaining balance of \$60,000 shall be paid in twelve (12) monthly payments of \$5,000 each through April 1, 2018. At March 21, 2016, the Company reclassified \$195,845 accounts payable and \$54,155 notes payable, related party to settlement payable in the accompanying balance sheet. As of June 30, 2017 and December 31, 2016, the outstanding balance due was \$45,000 and \$250,000, respectively.

**NOTE 8 – NOTES PAYABLE**

On July 7, 2014, the Company issued unsecured promissory notes in aggregate of \$545,218 in settlement of previously issued convertible debentures dated April 3, 2013 and related accrued interest. The promissory notes include monthly payments of principal and interest, at 12% per annum, of \$10,658 beginning August 15, 2014 through July 15, 2016 with the remaining unpaid balance due on or before July 15, 2016. During the six months ended June 30, 2017, the Company paid as full settlement the remaining outstanding promissory note of \$172,748.

**NOTE 9 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITIES**

BICX Holding Company LLC

On June 10, 2016, the Company issued to BICX Holding Company, LLC a \$2,500,000 senior secured convertible promissory note due June 10, 2019 and bearing interest at 8% per annum due annually beginning June 10, 2018.

Under the terms of the note, the note holder may, at any time, convert the unpaid principal of the note, or any portion thereof, into shares of the Company's common stock at an initial conversion price equal to 25% of the Company's total authorized common stock, determined at \$0.019 per share at the date of issuance. In addition, the note contained certain anti-dilution provisions, as defined.

The Company is required to maintain a cash balance of \$50,000 of the outstanding principal amount at all times, unrestricted and lien free (as amended).

BICX Holding had the right, until December 10, 2016, to purchase another convertible note from the Company in a principal amount of up to \$2,500,000 for a total aggregate purchase price of \$5,000,000 (the "Maximum Purchase Price"). The Company and BICX Holding agreed to extend this deadline and, on March 3, 2017, the parties entered into a First Amendment to the Note (the "First Amendment").

Pursuant to the First Amendment, BIXC Holding invested another \$1,660,000 for a total aggregate purchase price of \$4,160,000. Based on the amount invested, BICX Holding will return the Note and the Company will issue BICX Holding a new note for \$4,160,000 convertible into 42.43% of the Company's total authorized common stock. The other terms of the new note will be identical to the Note. Pursuant to the First Amendment, the parties agreed that BICX Holding does not have the right to appoint a consultant or, if the Company's common stock is listed on a national securities exchange, an independent member of the Board. In addition, the Company is not entitled to a break-up fee.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

On June 29, 2017, the parties entered into the Second Amendment to the Note Purchase Agreement and the March 2017 Note (the "Second Amendment"). The Second Amendment amends the March 2017 Note such that there is no longer an anti-dilution provision in the note. This provision in the March 2017 Note created a derivative liability for the Company which is no longer present.

In addition, the Second Amendment amends the March 2017 Note and the Note Purchase Agreement such that the Company agreed to not engage in any financing at a purchase price below the BIXC Holding purchase price. Finally, the Second Amendment amends the Note Purchase Agreement such that BICX Holding no longer has a right to participate in a subsequent financing in which the Company engages.

The note is secured by all of assets of the Company and is ranked senior to all of the Company's debt currently outstanding or hereafter, unless prohibited by law.

The Company has identified the embedded derivatives related to the above described note. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the Notes and to fair value as of each subsequent reporting date.

At inception of the 2017 additions, the Company determined the aggregate fair value of \$11,023,244 of embedded derivatives. The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 167.85% to 168.32%, (3) weighted average risk-free interest rate of 1.26% to 1.37%, (4) expected life of 2.21 to 2.25 years, and (5) estimated fair value of the Company's common stock of \$0.09 to 0.1122 per share.

The determined fair value of the debt derivatives of \$11,023,244 was charged as a debt discount up to the net proceeds of the note with the remainder of \$9,363,244 charged to current period operations as non-cash interest expense.

At June 29, 2017, the date of the Second Amendment modifying the above described note to eliminate the anti-dilutive provision, the Company determined the aggregate fair value the embedded derivatives of \$30,806,073, recognizing a gain on change in fair value of \$12,217,004 and reclassifying the determined fair value at June 29, 2017 of \$30,806,073 to equity. The fair value of the embedded derivatives was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 169.77%, (3) weighted average risk-free interest rate of 1.38%, (4) expected life of 1.95 years, and (5) estimated fair value of the Company's common stock of \$0.108 per share.

Hoppel/Vista Capital Promissory Notes payable

On October 20, 2016, the Company issued to an aggregate of \$220,000 Convertible Promissory Notes. The proceeds from the notes provides was up to an aggregate of \$200,000 in net proceeds after taking into consideration an Original Issue Discount ("OID") of \$20,000. The maturity date is six months from the date of issuance.

In connection with the issuance of the promissory notes, the Company issued 800,000 shares of its common stock as an inducement and is obligated to issue an additional 250,000 shares should the Company's common stock close below \$0.025 per share prior to full pay off of the notes. The fair value of the issued shares was charged as a debt discount at the time of issuance.

The Note is convertible after 180 days into shares of the Company's common stock at a conversion price equal to 60% discount to the lowest closing price of the common stock for the 25 trading days immediately prior the conversion date.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

During the six months ended June 30, 2017, the Company issued an aggregate of 13,662,000 shares of its common stock in full settlement of the above described notes.

Summary:

At June 30, 2017, the Company did not have convertible notes with embedded derivatives. The charge of the amortization of debt discounts and costs for the three and six months ended June 30, 2017 was \$370,913, and \$710,247; and \$114,471 and \$225,493 for the three and six months ended June 30, 2016, respectively, which was accounted for as interest expense.

**NOTE 10 – NOTES PAYABLE-RELATED PARTY**

As of June 30, 2017 and December 31, 2016, the Company received advances from Kent Emry former President of the Company, Scott Carley, and Neil Muller, former President of the Company as loans from related parties. The loans are payable on demand and without interest. In addition, the Company has issued unsecured, non-interest bearing demand notes to related parties. During the six months ended June 30, 2017, the Company paid \$15,000 on Mr. Emry's note and Neil Muller settled \$10,000 of outstanding debt. The balance outstanding as of June 30, 2017 and December 31, 2016 was \$22,980 and \$47,980, respectively.

On January 22, 2013, the Company issued a unsecured promissory note payable for \$200,000 due January 1, 2018, with a stated interest rate of 12% per annum beginning three months from issuance; payable monthly. Principal payments are due starting February 1, 2015 at \$6,650 per month. The lender has an option to convert the note to licensing rights for the State of Oregon. The Company currently is in default of the required interest payments initially due starting April 22, 2013. During the year ended December 31, 2014, the Company has paid \$36,390 principal and accrued interest towards the promissory note.

In connection with the issuance of the above described promissory note, the Company issued 950,000 (as amended) of its common stock on March 31, 2014.

The Company recorded a debt discount of \$11,250 based on the fair value of the Company's common stock at the issuance date of the promissory note. The discount is amortized ratably over the term on the notes. The note holder subsequently became an officer of the Company. The balance outstanding as of June 30, 2017 and December 31, 2016 was \$163,610, with unamortized debt discount of \$418 and \$828, respectively.

**NOTE 11 – WARRANT LIABILITY**

The Company issued warrants in conjunction with the issuance of certain convertible debentures. These warrants contain certain reset provisions. Therefore, in accordance with ASC 815-40, the Company reclassified the fair value of the warrant from equity to a liability at the date of issuance. Subsequent to the initial issuance date, the Company is required to adjust to fair value the warrant as an adjustment to current period operations.

At June 30, 2017, the fair value of the 1,155,000 warrants containing certain reset provisions were determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 169.32%, (3) weighted average risk-free interest rate of 1.24%, (4) expected life of 0.77 years, and (5) estimated fair value of the Company's common stock of \$0.108 per share.

The Company recorded a loss from change in fair value of warrant liability of debt derivatives of \$84,244 for the six months ended June 30, 2017.

At June 30, 2017, the warrant liability valued at \$111,146, the Company believes an event under the contract that would create an obligation to settle in cash or other current assets is remote and has classified the obligation as a long term liability.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

**NOTE 12 – STOCKHOLDERS' DEFICIT**

Preferred stock

The Company is authorized to issue 600,000 shares of preferred stock with no par value. As of June 30, 2017 and December 31, 2016, the Company had 80,000 shares of preferred stock and 160,000 shares of Series B preferred stock issued and outstanding.

Common stock

The Company is authorized to issue 525,000,000 shares of common stock with par value \$.001 per share. As of June 30, 2017 and December 31, 2016, the Company had 242,136,285 shares and 181,804,501 shares of common stock issued and outstanding.

In January 2017, the Company issued an aggregate of 228,118 shares of its common stock for services rendered valued at \$7,478 based on the underlying market value of the common stock at the date of issuance.

In February 2017, the Company issued 350,000 shares of its common stock for services rendered valued at \$25,830 based on the underlying market value of the common stock at the date of issuance.

In February 2017, the Company issued 43,666,666 shares of its common stock in exchange for proceeds of \$940,000.

In March 2017, the Company issued an aggregate of 13,662,000 shares of its common stock in settlement of \$220,000 convertible notes payable.

In April 2017, the Company issued an aggregate of 1,675,000 shares of its common stock for services rendered valued at \$62,850 based on the underlying market value of the common stock at the date of issuance.

In May 2017, the Company issued 750,000 shares of its common stock for services rendered valued at \$102,750 based on the underlying market value of the common stock at the date of issuance.

**NOTE 13 – STOCK OPTIONS AND WARRANTS**

*Options*

The following table summarizes the stock option activity for the six months ended June 30, 2017:

	<u>Shares</u>	<u>Weighted- Average Exercise Price</u>	<u>Weighted- Average Remaining Contractual Term</u>	<u>Aggregate Intrinsic Value</u>
Outstanding at December 31, 2016	47,850,000	\$ 0.04	8.9	\$ 326,700
Grants	-			
Exercised	-			
Expired	-		-	-
Outstanding at June 30, 2017	47,850,000	\$ 0.04	8.0	\$ 3,202,800
Exercisable at June 30, 2017	31,350,000	\$ 0.05	7.5	\$ 1,752,450

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company's stock price of \$0.108 as of June 30, 2017, which would have been received by the option holders had those option holders exercised their options as of that date.

The following table presents information related to stock options at June 30, 2017:

<b>Options Outstanding</b>			<b>Options Exercisable</b>		
<b>Exercise Price</b>	<b>Number of Options</b>	<b>Weighted Average Remaining Life In Years</b>			
			<b>Exercisable Number of Options</b>		
\$ 0.01-0.025	33,000,000	9.0	16,500,000		
0.0251-0.05	3,500,000	3.1	3,500,000		
0.051	11,350,000	6.8	11,350,000		
	<u>47,850,000</u>	<u>8.0</u>	<u>31,350,000</u>		

The stock-based compensation expense related to option grants was \$78,536 and \$157,071 during the three and six months ended June 30, 2017, respectively; and \$26,178 for the three and six months ended June 30, 2016.

As of June 30, 2017, stock-based compensation related to options of \$287,963 remains unamortized and is expected to be amortized over the weighted average remaining period of 1 year.

*Warrants:*

The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company's common stock:

<b>Warrants Outstanding</b>			<b>Warrants Exercisable</b>		
<b>Exercise Prices</b>	<b>Number Outstanding</b>	<b>Weighted Average Contractual Life (Years)</b>	<b>Weighted Average Exercise Price</b>	<b>Number Exercisable</b>	<b>Weighted Average Contractual Life (Years)</b>
\$ 0.25	1,275,000	2.02	\$ 0.25	1,275,000	2.02
1.00	1,155,000	0.75	1.00	1,155,000	0.75
\$ 0.58	2,430,000	1.42	\$ 0.61	2,430,000	1.42

The following table summarizes the warrant activity for the six months ended June 30, 2017:

	<b>Number of Shares</b>	<b>Weighted Average Exercise Price Per Share</b>
Outstanding at December 31, 2016	2,630,000	\$ 0.58
Issued	-	-
Exercised	-	-
Expired	(200,000)	0.25
Outstanding at June 30, 2017	<u>2,430,000</u>	<u>\$ 0.61</u>

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

**NOTE 14 – RELATED PARTY TRANSACTIONS**

The Company has an arrangement with Premier Aftercare Recovery Service, ("PARS"). PARS is a Company controlled by Neil Muller, a shareholder of the Company and prior officer of the Company, that provides consulting services to the Company. There is no formal agreement between the parties and the amount of remuneration was \$14,583 per month. During the three and six months ended June 30, 2017 and 2016, the Company incurred \$-0-, as consulting fees and expense reimbursements. As of June 30, 2017 and December 31, 2016, there was an unpaid balance of \$32,318 and \$64,638, respectively.

The Company has an arrangement with Felix Financial Enterprises ("FFE"). FFE is a Company controlled by Lourdes Felix, an officer of the Company that provides consulting services to the Company. Until June 17, 2016, there was no formal agreement between the parties and the amount of remuneration is \$14,583 per month. During the three and six months ended June 30, 2017, the Company incurred \$65,000 and \$106,500, respectively, and during the three and six months ended June 30, 2016, the Company incurred \$43,006 and \$86,756, respectively, as consulting fees. As of June 30, 2017 and December 31, 2016, there was an unpaid balance of \$25,000 and \$91,465, respectively.

On June 17, 2016, the Company entered into an executive service contract with Felix Financial Enterprises LLC to provide consulting services. The agreement is an at will agreement and provides for a base salary of \$160,000 per year, 11,200,000 stock options, extended previously issued options and an auto allowance.

The Company has an arrangement with Brady Granier, an officer of the Company. Until June 17, 2016 there was no formal agreement between the parties and the amount of remuneration is \$14,583 per month. For the three and six months ended June 30, 2017 the Company incurred \$0 and \$30,727, respectively and during the three and six months ended June 30, 2016, the Company incurred \$43,750 and \$87,500, respectively, as consulting fees. As of June 30, 2017 and December 31, 2016, there was an unpaid balance of \$-0- and \$64,481, respectively.

On June 17, 2016, the Company entered into an executive service contract with Brady Granier as the Company's President and Chief Executive Officer. The agreement is an at will agreement and provides for a base salary of \$175,000 per year, 10,600,000 stock options, extended previously issued options and an auto allowance.

The Company has an arrangement with Soupface LLC ("Soupface"). Soupface is a Company controlled by Brady Granier, an officer of the Company, that provides consulting services to the Company. There was no formal agreement between the parties and the amount of remuneration is \$14,583 per month. For the three and six months ended June 30, 2017 the Company incurred \$76,042 and \$90,625, respectively and during the three and six months ended June 30, 2016, the Company incurred \$0, as consulting fees. As of June 30, 2017 and December 31, 2016, there was an unpaid balance of \$25,000 and \$-0-, respectively.

On June 17, 2016, the Company entered into an executive service contract with Tom Welch as the Company's Vice President of Operations. The agreement is an at will agreement and provides for a base salary of \$140,000 per year, 11,200,000 stock options, extended previously issued options and an auto allowance.

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc. for the purpose of developing certain business lines. In connection with the formation, the, the newly formed sub issued 21.9% ownership to Brady Granier, Lourdes Felix and Kent Emry, current or former officers of the Company, with the Company retaining 78.1%. As of June 30, 2017, there were no significant transactions, assets or liabilities in BioCorRx Pharmaceuticals, Inc., or operations since its formation.

The above related parties are compensated as independent contractors and are subject to the Internal Revenue Service regulations and applicable state law guidelines regarding independent contractor classification. These regulations and guidelines are subject to judicial and agency interpretation, and it could be determined that the independent contractor classification is inapplicable.

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
**(unaudited)**

**NOTE 15 – CONCENTRATIONS**

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company's revenues earned from sale of products and services for the three months ended June 30, 2016 included 14%, 14%, 14% and 14% (aggregate of 56%) from four customers of the Company's total revenues.

The Company's revenues earned from sale of products and services for the six months ended June 30, 2016 included 11%, 15% and 10% (aggregate of 36%) from three customers of the Company's total revenues.

The Company did not have a concentration for the three and six months ended June 30, 2017.

Two customers accounted for 17% and 11% (aggregate of 28%) of the Company's total accounts receivable at June 30, 2017 and three customers accounted for 27%, 11% and 18% (aggregate of 56%) of the Company's total accounts receivable at December 31, 2016.

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.

**NOTE 16 – NON CONTROLLING INTEREST**

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the newly formed sub issued 21.9% ownership to officers of the Company with the Company retaining 78.1%. From inception through June 30, 2017, there were no significant transactions, assets or liabilities in BioCorRx Pharmaceuticals, Inc., or operations since its formation.

**NOTE 17 – FAIR VALUE MEASUREMENTS**

ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of June 30, 2017:

**BIOCORRX, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**JUNE 30, 2017**  
*(unaudited)*

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Warrant liability			111,146	111,146

Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of December 31, 2016:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Derivative liability	\$ -	\$ -	\$ 5,115,280	\$ 5,115,280
Warrant liability			26,903	26,903
Total	\$ -	\$ -	\$ 5,142,183	\$ 5,142,183

The table below sets forth a summary of changes in the fair value of the Company's Level 3 financial liabilities from December 31, 2016 through June 30, 2017:

	<u>Debt Derivative Liability</u>	<u>Warrant Liability</u>
Balance, December 31, 2016	5,115,280	26,903
Transfers in (out):		
Initial fair value of debt derivative at note issuance	11,023,244	-
Transfers out of Level 3 upon conversion and settlement of notes	(1,146,201)	-
Transfers out of Level 3 upon note modification	(30,806,073)	
Mark-to-market at June 30, 2017:		
Embedded derivative	15,813,750	84,243
Balance, June 30, 2017	\$ -0-	\$ 111,146

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*This Management's Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management's current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as "may" "will," "expect," "anticipate," "believe," "estimate" and "continue," or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.*

*Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to us could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that its assumptions are based upon reasonable data derived from and known about our business and operations and the business and operations of the Company. No assurances are made that actual results of operations or the results of our future activities will not differ materially from its assumptions. Factors that could cause differences include, but are not limited to, expected market demand for the Company's services, fluctuations in pricing for materials, and competition.*

### **Business Overview**

We are an addiction rehabilitation service company and developer of the BioCorRx Recovery Program headquartered in Anaheim, California. We were established in January 2010 and currently operating in Anaheim, California. The Company's current treatment program is called the BioCorRx Recovery Program. On January 7, 2014 we changed our name to BioCorRx Inc. to take advantage of unique branding of our BioCorRx Recovery Program and to look to acquire other addiction programs and healthcare related products and services. We operate within the *Specialty Hospitals, Expert Psychiatric* industry, specifically within the industry subsets of *Addiction Rehabilitation Hospital*.

The BioCorRx Recovery Program is used for the treatment of alcoholism and opioid addiction consisting of a naltrexone implant that is placed under the skin in the lower abdomen coupled with a counseling/life coaching program which includes a series of modules to be used by trained counselors usually within 16 sessions, as well as 12 months of peer recovery support and tracking.

BioCorRx Inc. has been granted an exclusive license to the proprietary implant by its developer. The license allows BioCorRx to license to physicians and medical groups experienced in treating alcoholism and opioid addiction dependency the right to order the proprietary implant from the compounding pharmacies that have been licensed and trained to make the implant by its developer. It also allows BioCorRx to sub-license the implant access to territories in the U.S. and abroad.

Our subsidiary, BioCorRx Pharmaceuticals, is focused on acquiring and the development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Specifically, the company is developing injectable and implantable naltrexone with the goal of future regulatory approval with the Food and Drug Administration. Our current strategy is to focus our development activities on BICX101 for the treatment of opioid addiction and alcoholism. Our pipeline also includes a naltrexone implant.

BICX101 is currently in development for the treatment of opioid and alcohol dependence as described below.

## [Table of Contents](#)

We initiated preclinical studies of BICX101, an injectable, sustained release naltrexone, for the treatment of opioid and alcohol use disorders, in December 2016, and this study is currently ongoing. On May 25, 2017 we announced that the U.S. Food & Drug Administration (FDA) had granted a pre-IND meeting to the Company to review the development plan to market BICX101. The meeting will take place on September 19, 2017. At the pre-IND meeting, the Company plans to seek guidance from the FDA on its proposal to file a New Drug Application (NDA) under Section 505(b)(2) for approval of BICX101, based on the FDA's previous determination of the safety and effectiveness of naltrexone for the treatment of opioid addiction and alcohol use disorders.

BioCorRx is not a licensed health care provider and does not provide health care services to patients. BioCorRx does not operate substance abuse clinics. BioCorRx makes the BioCorRx Recovery Program available to health care providers to utilize when the health care provider determines it is medically appropriate and indicated for his or her patients. Any physician or licensed alcohol addiction treatment provider is solely responsible for treatment options prescribed or recommended to his or her patients. At all times, such providers retain complete and exclusive authority, responsibility, supervision and control over their medical practice, their patients, the treatment that their patients receive and any decision to prescribe the implant to any of the provider's patients.

BioCorRx does not condition its license to health care providers accessing the implant on their making available the Counseling Program to the providers' patients although BioCorRx certainly encourages that providers do so.

BioCorRx has issued several license and distribution agreements to several unrelated third parties involving the establishment of alcoholism and opioid addiction rehabilitation and treatment centers and creating certain addiction rehabilitation programs. The Company continued to expand its operations in 2016 through distribution opportunities of its BioCorRx Recovery Program. There are over 15 licensed providers throughout the United States that offer the BioCorRx Recovery Program. The company's current focus will continue on wider distribution across the United States, branding of the BioCorRx Recovery Program and acquisition of healthcare related products and services. The Company is committed to continuing to provide excellent rehabilitation products and services to healthcare providers nationwide as it expands the distribution of the BioCorRx Recovery Program to a network of independent licensed clinics and licensed healthcare professionals.

### *Amendment to Convertible Note Purchase Agreement Entered into with BICX Holding Company LLC*

As previously disclosed, on June 14, 2016, the Company and BICX Holding Company LLC ("BICX Holding") entered into a Senior Secured Convertible Note Purchase Agreement (the "Note Purchase Agreement") and the Company issued and sold to BICX Holding an 8% Senior Secured Convertible Promissory Note (the "June 2016 Note") in the principal amount of \$2,500,000. BICX Holding is an entity controlled by Alpine Creek Capital Partners. In addition, as previously disclosed, on March 3, 2017, the parties entered into the First Amendment to the Note Purchase Agreement (the "First Amendment"). Pursuant to the First Amendment, BICX Holding invested another \$1,660,000 for a total aggregate purchase price of \$4,160,000. Based on the amount invested, the Company issued a new note to replace the June 2016 Note (the "March 2017 Note"). The main differences between the June 2016 Note and the March 2017 Note are that the principal owed to BICX Holding is now \$4,160,000 and the percentage of the Company's total authorized common stock as of March 3, 2017 into which the March 2017 Note is convertible is now 42.43%. The March 2017 Note matures on March 3, 2020.

On June 29, 2017, the parties entered into the Second Amendment to the Note Purchase Agreement and the March 2017 Note (the "Second Amendment"). The Second Amendment amends the March 2017 Note such that there is no longer an anti-dilution provision in the note. This provision in the March 2017 Note created a derivative liability for the Company which is no longer present.

In addition, the Second Amendment amends the March 2017 Note and the Note Purchase Agreement such that the Company agreed to not engage in any financing at a purchase price below the BICX Holding purchase price. Finally, the Second Amendment amends the Note Purchase Agreement such that BICX Holding no longer has a right to participate in a subsequent financing in which the Company engages.

The March 2017 Note remains a long-term debt obligation that is material to the Company. The March 2017 Note contains certain events of default and, in the event of default, BICX Holding may, at its option, consider the March 2017 Note immediately due and payable.

## **Results of Operations**

The following table summarizes changes in selected operating indicators of the Company, illustrating the relationship of various income and expense items to net sales for the respective periods presented (components may not add or subtract to totals due to rounding):

### **Three Months ended June 30, 2017 Compared with Three Months ended June 30, 2016**

Three months ended June 30,

**2017**

**2016**

Net Revenues	\$ 210,544	\$ 187,912
Total Operating Expenses	(997,162)	(600,204)
Gain on settlement of debt	285,924	-
Net Interest Expense	(459,064)	(223,127)
Gain (loss) on change in derivative liability	<u>12,263,680</u>	<u>(438,344)</u>
Net income (loss)	<u>\$11,303,922</u>	<u>\$(1,073,763)</u>

[Table of Contents](#)

**Revenues**

Sales for the three months ended June 30, 2017 were \$210,544 compared with \$187,912 for the three months ended June 30, 2016, reflecting an increase of 12%.

The increase in revenue is directly related to the increased number of patients treated at licensed clinics and an increase in BioCorRx Recovery Program distribution.

**Total Operating Expenses**

Total operating expenses for the three months ended June 30, 2017 and 2016 were \$997,162 and \$600,204, respectively, reflecting an increase of \$396,958. The primary reason for the increase in 2017 is an increase in service provider costs as compared to 2016.

In addition, comparing the three months ended June 30, 2017 to June 30, 2016, consulting and investor relations fees increased from \$194,643 to \$335,906, accounting and legal fees decreased from \$143,235 to \$40,955, advertising decreased from \$70,222 to \$44,132, and rent increased from \$4,451 to \$8,978. In addition, we incurred \$244,136 in stock based compensation expense in 2017 compared to \$91,069 in 2016.

**Gain on settlement of debt**

During the three months ended June 30, 2017, we settled outstanding accounts and other payables, realizing a gain on settlement of debt of \$285,924 as compared to \$0 for the same comparable period, last year.

**Gain (loss) on change in Fair Value of Derivative Liability**

During the three months ended June 30, 2017, we had outstanding convertible debt and warrants with variable conversion provisions that had the possibility of exceeding our common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provision of this note. As such, we are required to determine the fair value of this derivative and mark to market each reporting period. For the three months ended June 30, 2017, we incurred a \$12,263,680 gain on change in fair value of our derivative liabilities compared to \$438,344 loss in the same period, last year. On June 29, 2017, pursuant to the Second Amendment, we modified our outstanding convertible debt with embedded derivatives significantly reducing the carrying value on our balance sheet of these liabilities as of June 30, 2017.

**Interest Expense**

Interest expense for the three months ended June 30, 2017 and 2016 were \$459,064 and \$223,127, respectively, the increase is due to debt discount amortization and a non-cash interest charge.

**Net Loss**

For the three months ended June 30, 2017, the Company experienced a net income of \$11,303,922 compared with a net loss of \$1,073,763 for the three months ended June 30, 2016. The decrease in net loss to net income is primarily due to the gain on change in fair value of derivative liabilities.

**Six Months ended June 30, 2017 Compared with Six Months ended June 30, 2016**

Six months ended June 30,

	<u>2017</u>	<u>2016</u>
Net Revenues	\$ 344,771	\$ 418,325
Total Operating Expenses	(1,543,732)	(1,165,273)
Gain on settlement of debt	285,924	-
Net Interest Expense	(10,220,569)	(388,359)
Loss on change in derivative liability	(15,897,993)	(467,041)
Net loss	<u>\$(27,031,599)</u>	<u>\$(1,602,348)</u>

## [Table of Contents](#)

### **Revenues**

Sales for the six months ended June 30, 2017 were \$344,771 compared with \$418,325 for the six months ended June 30, 2016, reflecting a decrease of 18%.

The decrease in revenue is directly related to the decreased number of patients treated at licensed clinics and a decrease in BioCorRx Recovery Program distribution.

### **Total Operating Expenses**

Total operating expenses for the six months ended June 30, 2017 and 2016 were \$1,543,732 and \$1,165,273, respectively, reflecting an increase of \$378,459. The primary reason for the increase in 2017 is an increase in service provider costs as compared to 2016.

In addition, comparing the six months ended June 30, 2017 to June 30, 2016, consulting and investor relations fees increased from \$343,276 to \$561,497, accounting and legal fees decreased from \$186,8045 to \$92,725, advertising decreased from \$138,744 to \$63,771, and rent increased from \$9,322 to \$19,916. In addition, we incurred \$355,979 in stock based compensation in 2017 compared to \$101,217 in 2016.

### **Gain on settlement of debt**

During the six months ended June 30, 2017, we settled outstanding accounts and other payables, realizing a gain on settlement of debt of \$285,924 as compared to \$0 for the same comparable period, last year.

### **Gain (loss) on change in Fair Value of Derivative Liability**

During the six months ended June 30, 2017, we had outstanding convertible debt and warrants with variable conversion provisions that had the possibility of exceeding our common shares authorized when considering the number of possible shares that may be issuable to satisfy settlement provision of this note. As such, we are required to determine the fair value of this derivative and mark to market each reporting period. For the six months ended June 30, 2017, we incurred a \$15,897,993 loss on change in fair value of our derivative liabilities compared to a \$467,041 loss in the same period, last year. The primary driver for the current period loss was the increase in our stock price. On June 29, 2017, pursuant to the Second Amendment, we modified our outstanding convertible debt with embedded derivatives significantly reducing the carrying value on our balance sheet these liabilities as of June 30, 2017.

### **Interest Expense**

Interest expense for the six months ended June 30, 2017 and 2016 were \$10,220,569 and \$388,359, respectively, the increase is due to debt discount amortization and a non-cash interest charge.

### **Net Loss**

For the six months ended June 30, 2017, the Company experienced a net loss of \$27,031,599 compared with a net loss of \$1,602,348 for the six months ended June 30, 2016. The increase in net loss is primarily due to the loss on change in fair value of derivative liabilities and non-cash interest charges.

### **Liquidity and Capital Resources**

As of June 30, 2017, we had cash of approximately \$845,000. The following table provides a summary of our net cash flows from operating, investing, and financing activities.

Six months ended June 30,

[Table of Contents](#)

	<u>2017</u>	<u>2016</u>
Net cash used in operating activities	\$(1,659,640)	\$(1,010,785)
Net cash used in investing activities	-	(87,406)
Net cash provided by financing activities	<u>2,412,252</u>	<u>2,052,948</u>
Net increase in cash	752,612	954,757
Cash, beginning of period	<u>92,455</u>	<u>220,060</u>
Cash, end of period	\$ 845,067	\$ 1,174,817

On June 10, 2016, the Company issued to BICX Holding Company, LLC a \$2,500,000 senior secured convertible promissory note due June 10, 2019 and bearing interest at 8% per annum due annually beginning June 10, 2018.

Pursuant to the First Amendment, BIXC Holding invested another \$1,660,000 in 2017 for a total aggregate purchase price of \$4,160,000. Based on the amount invested, BICX Holding returned the Note and the Company issued BICX Holding a new note for \$4,160,000 convertible into 42.43% of the Company's total authorized common stock. The other terms of the new note will be identical to the Note. Pursuant to the First Amendment, the parties agreed that BICX Holding does not have the right to appoint a consultant or, if the Company's common stock is listed on a national securities exchange, an independent member of the Board. In addition, the Company is not entitled to a break-up fee.

The Company is required to maintain a cash balance of \$50,000 (as amended) at all times, unrestricted and lien free.

The note is secured by all of assets of the Company and is ranked senior to all of the Company's debt currently outstanding or hereafter, unless prohibited by law.

Currently we have no material commitments for capital expenditures as of June 30, 2017. We have historically sought and continue to seek financing from private sources to move our business plan forward. In order to satisfy the financial commitments, we had relied upon private party financing that has inherent risks in terms of availability and adequacy of funding.

For the next twelve months, we anticipate that we will need to supplement our revenues with additional capital investment or debt to ensure that we will have adequate cash to provide the minimum operating cash requirements to continue as a going concern. There can be no guarantee or assurance that we can raise adequate capital from outside sources. If we are unable to raise funds when required or on acceptable terms, we have to significantly scale back, or discontinue our operations.

***Net Cash Flow From Operating Activities***

Net Cash used in operating activities was \$1,659,640 for the six months ended June 30, 2017 compared to \$1,010,785 used in operating activities the six months ended June 30, 2016. The increase was primarily due to the increased operating costs and expenses incurred in 2017 along with a net decrease in operating liabilities of \$469,013.

***Net Cash Flow From Investing Activities***

Net cash used in investing activities was \$-0- for the six months ended June 30, 2017 compared to \$87,406 used in investing activities during the six months ended June 30, 2016, which were primarily due to payments for intellectual property, purchase of equipment and lease deposit in 2016.

## [Table of Contents](#)

### ***Net Cash Flow From Financing Activities***

Net cash provided by financing activities increased by \$359,304, from \$2,052,948 provided by financing activities for the six months ended June 30, 2016 to \$2,412,252 cash provided by financing activities for the six months ended June 30, 2017. The increase is primarily from \$1,660,000 received from issuance of convertible note and \$940,000 received from the sale of our common stock, net with repayments of notes payable of \$187,748 as compared to \$2,264,448 from issuance of notes, net with \$211,500 repayments of notes payable in 2016.

### **Going Concern**

The Company's financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern. This contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of June 30, 2017 and December 31, 2016, the Company has a working capital deficit of \$202,186 and \$2,350,268, and an accumulated deficit of \$46,166,464 and \$19,134,865. We will be dependent upon the raising of additional capital through placement of our common stock in order to implement the Company's business plan or by using outside financing. There can be no assurance that the Company will be successful in these situations in order to continue as a going concern. The Company is funding its operations by additional borrowings and some shareholder advances.

### **Off Balance Sheet Arrangements**

We do not have any off balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, sales or expenses, results of operations, liquidity or capital expenditures, or capital resources that are material to an investment in our securities.

### **Critical Accounting Policies**

#### Use of Estimates and Assumptions

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of stock-based compensation, derivative and warrant liabilities, the fair value of other equity and debt instruments and allowance for doubtful accounts.

#### Revenue Recognition

We generate revenue from services and product sales. Revenue is recognized in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition ("ASC 605-10") which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the services delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related revenue are recorded. We defer any revenue for which the services have not been performed or are subject to refund until such time that the we and the customer jointly determine that the services has been performed or no refund will be required.

## Table of Contents

We license proprietary products and protocols to customers under licensing agreements that allow those customers to utilize the products and protocols in services they provide to their customers. The timing and amount of revenue recognized from license agreements depends upon a variety of factors, including the specific terms of each agreement. Such agreements are reviewed for multiple elements. Multiple elements can include amounts related to initial non-refundable license fees for the use of our products and protocols and additional royalties on covered services.

Revenue is only recognized after all of the following criteria are met: (1) written agreements have been executed; (2) delivery of product or intellectual property rights has occurred; (3) fees are fixed or determinable; and (4) collectability of fees is reasonably assured.

Under these license agreements, we receive an initial non-refundable license fee and in some cases, additional running royalties. Generally, we defer recognition of non-refundable upfront fees if it has continuing performance obligations without which the right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of its performance under the other elements of the arrangement. License fees collected from Licensees but not yet recognized as income are recorded as deferred revenue and amortized as income earned over the expected economic life of the related contract.

### Deferred Revenue

We, from time to time, collect initial license fees when license agreements are signed and become effective. License fees collected from Licensees but not yet recognized as income are recorded as deferred revenue and amortized as income earned over the economic life of the related contract.

### Derivative Financial Instruments

We account for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At June 30, 2017 and December 31, 2016, we did not have any derivative instruments that were designated as hedges.

During the six months ended June 30, 2017 and December 31, 2016, we had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions.

Stock-Based Compensation

Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty's performance is complete.

Recent Accounting Pronouncements

There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company's financial position, results of operations or cash flows.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not required under Regulation S-K for "smaller reporting companies."

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

As required under Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2017. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of June 30, 2017 were not effective, for the same reasons as previously disclosed under Item 9A. "Controls and Procedures" in our Annual Report on Form 10-K for our fiscal year ended December 31, 2016 filed with the Securities and Exchange Commission ("SEC") on April 13, 2017.

**Changes in Internal Controls over Financial Reporting**

There have been no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-(f) of the Exchange Act) that occurred during the our last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

From time to time, we may be engaged in various lawsuits and legal proceedings in the ordinary course of our business. Except as described below, we are currently not aware of any legal proceedings the ultimate outcome of which, in our judgment based on information currently available, would have a material adverse effect on our business, financial condition or results of operations. We are currently not a party to any material legal proceedings or claims not previously disclosed on Form 8-K.

**ITEM 1A. RISK FACTORS**

Not required under Regulation S-K for "smaller reporting companies."

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None

**ITEM 4. MINE SAFETY DISCLOSURES.**

Not applicable.

**ITEM 5. OTHER INFORMATION.**

Not Applicable.

Table of Contents

**ITEM 6. EXHIBITS.**

<a href="#"><u>10.1</u></a>	<a href="#"><u>Second Amendment to Senior Secured Convertible Note Purchase Agreement and Senior Secured Convertible Note by and between the Company and BICX Holding Company LLC, dated June 29, 2017 (incorporated herein by reference to Exhibit 10.1 to the Company's Form 8-K filed on July 6, 2017)</u></a>
<a href="#"><u>31.1</u></a>	<a href="#"><u>Certifications of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *</u></a>
<a href="#"><u>31.2</u></a>	<a href="#"><u>Certifications of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *</u></a>
<a href="#"><u>32.1</u></a>	<a href="#"><u>Certifications of Chief Executive Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +</u></a>
<a href="#"><u>32.2</u></a>	<a href="#"><u>Certifications of Chief Financial Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +</u></a>
101.INS	XBRL Instance Document *
101.SCH	XBRL Taxonomy Extension Schema Document *
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document *
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document *
101.LAB	XBRL Taxonomy Extension Label Linkbase Document *
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document *

\* Filed herewith

+ In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**BIOCORRX INC.**

Date: August 11, 2017

By: /s/ Brady Granier  
Brady Granier  
President and Chief Executive Officer

Date: August 11, 2017

By: /s/ Lourdes Felix  
Lourdes Felix  
Chief Financial Officer and Chief  
Operating Officer

## CERTIFICATION

I, Brady Granier, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: August 11, 2017

By: /s/ Brady Grainer  
Brady Grainer  
President and Chief Executive Officer

## CERTIFICATION

I, Lourdes Felix, certify that:

1. I have reviewed this quarterly report on Form 10-Q of BioCorRx Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonable likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: August 11, 2017

By: /s/ Lourdes Felix

Lourdes Felix  
Chief Financial Officer and Director

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Brady Grainer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended June 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioCorRx Inc.

Date: August 11, 2017

By: /s/ Brady Grainer  
Brady Grainer  
President and Chief Executive Officer

**CERTIFICATIONS OF CHIEF FINANCIAL OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Lourdes Felix, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of BioCorRx Inc. on Form 10-Q for the quarter ended June 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of BioCorRx Inc.

Date: August 11, 2017

By: */s/ Lourdes Felix*

\_\_\_\_\_  
Lourdes Felix

Chief Financial Officer and Director